Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Giulia Benevolo

Showing results (21-30 of 122) with videos related to

Pageof 13
Sort By:
Plos One|August 24, 2021
Immunohistochemical typing of amyloid in fixed paraffin-embedded samples by an automatic procedure: Comparison with immunofluorescence data on fresh-frozen tissueAntonella Barreca, Emanuel Bottasso, Francesca Veneziano, et al.
Annals of Hematology|May 28, 2018
Ruxolitinib for the treatment of inadequately controlled polycythemia vera without splenomegaly: 80-week follow-up from the RESPONSE-2 trialMartin Griesshammer, Guray Saydam, Francesca Palandri, et al.
Hemasphere|February 20, 2020
Droplet Digital PCR Assay for <i>MYD88</i> <sup></sup> : Clinical Applications in Waldenström MacroglobulinemiaMariella Lo Schirico, Martina Ferrante, Irene Dogliotti, et al.
The Lancet. Oncology|December 6, 2016
Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): a randomised, open-label, phase 3b studyFrancesco Passamonti, Martin Griesshammer, Francesca Palandri, et al.
Seminars in Hematology|April 26, 2023
Report of Consensus Panel 6 from the 11 th International Workshop on Waldenström's Macroglobulinemia on Management of Waldenström's Macroglobulinemia Related AmyloidosisGiampaolo Merlini, Shayna Sarosiek, Giulia Benevolo, et al.
Annals of Hematology|April 18, 2018
Yttrium-90 ibritumomab tiuxetan (Zevalin) followed by BEAM (Z-BEAM) conditioning regimen and autologous stem cell transplantation (ASCT) in relapsed or refractory high-risk B-cell non-Hodgkin lymphoma (NHL): a single institution Italian experienceChiara Ciochetto, Barbara Botto, Roberto Passera, et al.
Blood|December 7, 2006
Bortezomib, melphalan, prednisone, and thalidomide for relapsed multiple myelomaAntonio Palumbo, Maria Teresa Ambrosini, Giulia Benevolo, et al.
Cancer|July 7, 2011
Fludarabine plus cyclophosphamide and rituximab in Waldenstrom macroglobulinemia: an effective but myelosuppressive regimen to be offered to patients with advanced diseaseAlessandra Tedeschi, Giulia Benevolo, Marzia Varettoni, et al.
Clinical Lymphoma, Myeloma & Leukemia|March 16, 2013
Fludarabine, cyclophosphamide, and rituximab in salvage therapy of Waldenström's macroglobulinemiaAlessandra Tedeschi, Francesca Ricci, Maria Cecilia Goldaniga, et al.
Haematologica|January 8, 2010
Melphalan, prednisone, thalidomide and defibrotide in relapsed/refractory multiple myeloma: results of a multicenter phase I/II trialAntonio Palumbo, Alessandra Larocca, Mariella Genuardi, et al.
Pageof 13

Showing results (21-30 of 122) with videos related to

Sort By:
Pageof 13
Plos One|August 24, 2021
Immunohistochemical typing of amyloid in fixed paraffin-embedded samples by an automatic procedure: Comparison with immunofluorescence data on fresh-frozen tissueAntonella Barreca, Emanuel Bottasso, Francesca Veneziano, et al.
Annals of Hematology|May 28, 2018
Ruxolitinib for the treatment of inadequately controlled polycythemia vera without splenomegaly: 80-week follow-up from the RESPONSE-2 trialMartin Griesshammer, Guray Saydam, Francesca Palandri, et al.
Hemasphere|February 20, 2020
Droplet Digital PCR Assay for <i>MYD88</i> <sup></sup> : Clinical Applications in Waldenström MacroglobulinemiaMariella Lo Schirico, Martina Ferrante, Irene Dogliotti, et al.
The Lancet. Oncology|December 6, 2016
Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): a randomised, open-label, phase 3b studyFrancesco Passamonti, Martin Griesshammer, Francesca Palandri, et al.
Seminars in Hematology|April 26, 2023
Report of Consensus Panel 6 from the 11 th International Workshop on Waldenström's Macroglobulinemia on Management of Waldenström's Macroglobulinemia Related AmyloidosisGiampaolo Merlini, Shayna Sarosiek, Giulia Benevolo, et al.
Annals of Hematology|April 18, 2018
Yttrium-90 ibritumomab tiuxetan (Zevalin) followed by BEAM (Z-BEAM) conditioning regimen and autologous stem cell transplantation (ASCT) in relapsed or refractory high-risk B-cell non-Hodgkin lymphoma (NHL): a single institution Italian experienceChiara Ciochetto, Barbara Botto, Roberto Passera, et al.
Blood|December 7, 2006
Bortezomib, melphalan, prednisone, and thalidomide for relapsed multiple myelomaAntonio Palumbo, Maria Teresa Ambrosini, Giulia Benevolo, et al.
Cancer|July 7, 2011
Fludarabine plus cyclophosphamide and rituximab in Waldenstrom macroglobulinemia: an effective but myelosuppressive regimen to be offered to patients with advanced diseaseAlessandra Tedeschi, Giulia Benevolo, Marzia Varettoni, et al.
Clinical Lymphoma, Myeloma & Leukemia|March 16, 2013
Fludarabine, cyclophosphamide, and rituximab in salvage therapy of Waldenström's macroglobulinemiaAlessandra Tedeschi, Francesca Ricci, Maria Cecilia Goldaniga, et al.
Haematologica|January 8, 2010
Melphalan, prednisone, thalidomide and defibrotide in relapsed/refractory multiple myeloma: results of a multicenter phase I/II trialAntonio Palumbo, Alessandra Larocca, Mariella Genuardi, et al.
Pageof 13